Girindus, RiboTask Sign Commercial Pact

Girindus signed a commercial collaboration agreement with RiboTask, a small-scale provider of oligonucleotides for use in R&D. RiboTask will gain access to Girindus’ worldwide sales and marketing team and Girindus will have the ability to offer its customers seamless manufacture of a wide variety of oligonucleotides from the mg quantity to commercial kg quantities.

“Prof. Jesper Wengel, chairman of the board of RiboTask, has long been recognized as one of the leaders in the oligonucleotide field,” said Dr. Mark Laskovics, president and chief operating officer of Girindus America. “RiboTask has been built into a world-class organization to provide a range of oligonucleotides, particularly oligonucleotides possessing complex sequences. We are delighted that our two organizations will work together to provide the best possible solution for our customers.”

“We have seen in Girindus the technical and financial staying power to be the pre-eminent force in the oligonucleotide field,” stated Prof. Wengel. “We are delighted to enter into a partner relationship with Girindus.”